Goldman Sachs Group Inc. Trims Stake in Mural Oncology PLC $MURA

Goldman Sachs Group Inc. lowered its position in Mural Oncology PLC (NASDAQ:MURA) by 5.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 109,922 shares of the company’s stock after selling 5,906 shares during the quarter. Goldman Sachs Group Inc. owned about 0.64% of Mural Oncology worth $139,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in MURA. Armistice Capital LLC increased its stake in Mural Oncology by 1.3% in the 1st quarter. Armistice Capital LLC now owns 1,722,000 shares of the company’s stock worth $2,170,000 after buying an additional 22,000 shares during the period. Squarepoint Ops LLC increased its stake in Mural Oncology by 1.4% in the 4th quarter. Squarepoint Ops LLC now owns 175,502 shares of the company’s stock worth $565,000 after buying an additional 2,470 shares during the period. Two Sigma Investments LP increased its stake in Mural Oncology by 12.0% in the 4th quarter. Two Sigma Investments LP now owns 65,150 shares of the company’s stock worth $210,000 after buying an additional 6,993 shares during the period. Northern Trust Corp increased its stake in Mural Oncology by 22.0% in the 4th quarter. Northern Trust Corp now owns 39,966 shares of the company’s stock worth $129,000 after buying an additional 7,197 shares during the period. Finally, Two Sigma Advisers LP purchased a new position in Mural Oncology in the 4th quarter worth about $84,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Mural Oncology Stock Down 0.5%

Shares of Mural Oncology stock opened at $2.08 on Tuesday. The firm’s 50 day moving average price is $2.05 and its 200-day moving average price is $2.29. Mural Oncology PLC has a 52-week low of $0.95 and a 52-week high of $4.74. The company has a market cap of $36.05 million, a P/E ratio of -0.24 and a beta of 3.00.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings data on Monday, August 4th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.64). As a group, equities research analysts forecast that Mural Oncology PLC will post -7.54 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded shares of Mural Oncology from a “hold” rating to a “strong sell” rating in a research note on Sunday, August 10th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.